z-logo
Premium
Multiple granulomatous inflammation in the minor salivary glands: A proposed new entity, allergic granulomatous sialadenitis
Author(s) -
Irié Tarou,
Maeda Yukiko,
Aida Tadateru,
Sumitani Kaname,
Nagumo Masao,
Tachikawa Tetsuhiko
Publication year - 2004
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2004.01768.x
Subject(s) - medicine , pathology , giant cell , granuloma , sialadenitis , sarcoidosis , langhans giant cell , salivary gland , eosinophilic , caseous necrosis , epithelioid cell , tuberculosis , immunohistochemistry
We report a patient who presented with multiple small submucosal nodules with granulomatous inflammation in the minor salivary glands of the oral cavity. A 43‐year‐old woman presented with a 1‐week history of multiple small submucosal nodules in her oral cavity after having taken medicine for abdominal pain. The patient did not have a history of fever, rectal bleeding, skin lesions or arthritis, but did have a history of drug allergy and bronchial asthma. Histopathological examination of the submucosal nodules showed sialadenitis with marked infiltration of lymphocytes, eosinophilic cells, macrophages and Langhans‐type or foreign‐body‐type multinucleate giant cells. The macrophages tended to be aggregated and appeared to have caused immature granuloma formation without caseous necrosis. Degranulated eosinophilic cells were numerous. Sarcoidosis, Crohn's disease, tuberculosis and atypical mycobacterial infection were not identified by medical examination. Three weeks after discontinuing the medication the patient was seen again at a follow‐up visit. Multiple submucosal small nodules and other symptoms were not evident at that time. This case report may represent a new entity of salivary gland disease that we tentatively refer to as ‘allergic granulomatous sialadenitis’.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here